Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study.

Authors: Brooks, Jennifer D; Cairns, Paul; Shore, Roy E; Klein, Catherine B; Wirgin, Isaac; Afanasyeva, Yelena; Zeleniuch-Jacquotte, Anne

Published In Cancer Epidemiol, (2010 Dec)

Abstract: Promoter methylation of tumor suppressor genes is a frequent and early event in breast carcinogenesis. Paired tumor tissue and serum samples from women with breast cancer show that promoter methylation is detectable in both sample types, with good concordance. This suggests the potential for these serum markers to be used for breast cancer detection.The current study was a case-control study nested within the prospective New York University Women's Health Study cohort aimed to assess the ability of promoter methylation in serum to detect pre-clinical disease. Cases were women with blood samples collected within the 6 months preceding breast cancer diagnosis (n=50). Each case was matched to 2 healthy cancer-free controls and 1 cancer-free control with a history of benign breast disease (BBD).Promoter methylation analysis of four cancer-related genes: -RASSF1A, GSTP1, APC and RARβ2, - was conducted using quantitative methylation-specific PCR. Results showed that the frequency of methylation was lower than expected among cases and higher than expected among controls. Methylation was detected in the promoter region of: RASSF1A in 22.0%, 22.9% and 17.2% of cases, BBD controls and healthy controls respectively; GSTP1 in 4%, 10.4% and 7.1% respectively; APC in 2.0%, 4.4% and 4.2% respectively and RARβ2 in 6.7%, 2.3% and 1.1% respectively.Methylation status of the four genes included in this study was unable to distinguish between cases and either control group. This study highlights some methodological issues to be addressed in planning prospective studies to evaluate methylation markers as diagnostic biomarkers.

PubMed ID: 20627767 Exiting the NIEHS site

MeSH Terms: Adult; Aged; Biomarkers, Tumor/blood*; Breast Neoplasms/blood; Breast Neoplasms/diagnosis; Breast Neoplasms/genetics*; Case-Control Studies; Cohort Studies; DNA Methylation*; Early Detection of Cancer/methods; Female; Follow-Up Studies; Humans; Middle Aged; Polymerase Chain Reaction; Promoter Regions, Genetic; Prospective Studies

to Top